• Explore /
  • Poster
  • / Activating genomic mutations in the mTOR pathway predict responses to everolimus and temsirolimus in patients with metastatic renal cell carcinoma (mRCC): Results from a large multi-institutional cohort.

Activating genomic mutations in the mTOR pathway predict responses to everolimus and temsirolimus in patients with metastatic renal cell carcinoma (mRCC): Results from a large multi-institutional cohort.

Abstract Poster

Authors

null

Andre Poisl Fay

Oncology Service and Oncology Research Unit, HSL/PUCRS, Porto Alegre, Brazil

Andre Poisl Fay , David J. Kwiatkowski , Kathryn P. Gray , Aaron Thorner , Brian I. Rini , Neeraj Agarwal , Thai Huu Ho , Jiaxi Song , Pablo M Barrios , Laurence Albiges , Eliezer Mendel Van Allen , Katherine Maragaret Krajewski , Camillo Porta , Sumanta Kumar Pal , Joaquim Bellmunt , David F. McDermott , Daniel Yick Chin Heng , Sabina Signoretti , Toni K. Choueiri

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Genitourinary (Nonprostate) Cancer

Track

Genitourinary Cancer

Sub Track

Kidney Cancer

Citation

J Clin Oncol 33, 2015 (suppl; abstr 4519)

DOI

10.1200/jco.2015.33.15_suppl.4519

Abstract #

4519

Poster Bd #

189

Abstract Disclosures

Similar Posters

First Author: Bradley Alexander McGregor

Poster

2017 ASCO Annual Meeting

Pathogenic variants in DNA damage response (DDR) genes in patients with advanced solid tumors.

Pathogenic variants in DNA damage response (DDR) genes in patients with advanced solid tumors.

First Author: Ecaterina Elena Ileana Dumbrava

First Author: Martin Henner Voss

First Author: Andrea P. Myers